Trials
16 active
19 in total · 5 in the EU
What this is
- How it works
- Copies two gut hormones, GLP-1 and GIP, to lower appetite and blood sugar. Same approach as Mounjaro and Zepbound.GIP/GLP-1 receptor dual agonist
- Tested for
- Depressive Disorder, Major (2 trials), Alcohol Use Disorder (2 trials), Irritable Bowel Syndrome (2 trials), Overweight (2 trials), Obesity (2 trials), Smoking, Constipation, Diarrhea and 7 more
- Main trialPhase 3
- “This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.”In the company’s words, NCT07412756 on ClinicalTrials.gov
- Other names
- LY3537031
Other drugs for Depressive Disorder, Major
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up12
- NovPhase 1 trial completes · ClinicalTrials.gov
- NovPhase 1 trial completes · ClinicalTrials.gov
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07928245
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2028 | A Study of Brenipatide in Adult Participants With Major Depressive Disorder | |
| Phase 3Recruiting | Apr 2028 | A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder | |
| Phase 3Recruiting | Apr 2028 | A Study of Brenipatide in Participants With Alcohol Use Disorder | |
| Phase 3Recruiting | Dec 2028 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | |
| Phase 2Recruiting | Feb 2027 | A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse | |
| Phase 2Recruiting | Jul 2027 | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | |
| Phase 2Recruiting | Sep 2027 | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | |
| Phase 2Recruiting | Nov 2027 | A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) | |
| Phase 2Recruiting | Nov 2027 | A Study of Brenipatide in Adult Participants With Schizophrenia | |
| Phase 2Recruiting | Mar 2028 | A Study of Brenipatide in Participants With Opioid Use Disorder | |
| Phase 2Recruiting | Apr 2028 | A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | |
| Phase 2Not yet recruiting | May 2028 | A Study of Brenipatide in Participants With Major Depressive Disorder | |
| Phase 2Recruiting | May 2028 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | |
| Phase 1Recruiting | Nov 2026 | A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | |
| Phase 1Active, not recruiting | Nov 2026 | A Study of LY3537031 in Overweight, Obese, and Healthy Participants | |
| Phase 1Active, not recruiting | Feb 2027 | A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity | |
| Phase 1Completed | 4 Jun 2021 | A Study of LY3537031 in Healthy Participants | |
| Phase 1Completed | 16 Apr 2026 | A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment | |
| Phase 1Completed | 17 Jul 2026 | A Study of How the Body Absorbs LY3537031 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026